Patient Information Website
Click here to access
LUVOX CR information for
patients.
Prescribing Information
Download the full
prescribing information.
Obsessive Compulsive Disorder (OCD)/Social Anxiety Disorder (SAD) Resources and Links
Below is a listing of some useful links and resources.
These websites and organizations are listed for the benefit of those that may be interested in them. This site does not promote any of the websites or organizations listed.
Anxiety Disorders Association of America (ADAA)
ADAA is a national, non-profit organization. Their objective is to inform the public, healthcare professionals, and legislators about the real and serious problems that anxiety disorders present. They see these disorders as treatable and advocate early diagnosis and treatment as the first steps to a cure.
National Alliance on Mental Illness (NAMI)
NAMI is an organization made up of people who suffer from serious mental illnesses. Their goal is to improve the day-to-day lives of these people and their families.
National Institute of Mental Health (NIMH)
NIMH is an organization that believes research on mind, brain, and behavior holds the key to understanding and reducing the problems associated with mental illness and behavioral disorders.
National Mental Health Information Center Services Locator
The National Mental Health Information Center Services Locator is a site that provides extensive information about where to find mental health resources and services throughout the United States.
Obsessive Compulsive Foundation (OCF)
OCF is an international, not-for-profit organization made up of people with OCD and related disorders. This site focuses on the lives of these individuals and how the disorder affects family, social, and work environments. They encourage family, friends, and coworkers of those dealing with OCD to become involved.
OCDCenter.org
Informational resource center about OCD, its symptoms, and treatment information.
SocialAnxietyCenter.org
Informational resource center about SAD, its symptoms, and treatment information.
WebMD on Obsessive Compulsive Disorder (OCD)
WebMD provides valuable health information, tools for managing your health, and support to those who seek information.
WebMD on Social Anxiety Disorder (SAD)
WebMD provides valuable health information, tools for managing your health, and support to those who seek information.
Once-A-Day LUVOX CR® (fluvoxamine maleate) Extended-Release Capsules are indicated for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD).
Important Safety Information
CONTRAINDICATIONS
The use of alosetron, tizanidine, thioridazine, or pimozide with LUVOX CR Capsules is contraindicated. The use of MAO inhibitors in combination with LUVOX CR Capsules, or within 14 days of discontinuing treatment with LUVOX CR Capsules, is contraindicated (see WARNINGS and PRECAUTIONS). LUVOX CR Capsules are also contraindicated in patients with a history of hypersensitivity to fluvoxamine maleate or any of its excipients.
ADVERSE EVENTS
In clinical trials, the most commonly observed adverse events with an incidence of ≥5% and at least twice that of placebo were nausea, somnolence, asthenia, diarrhea, anorexia, tremor, and sweating. Overall, these side effects were mild to moderate in severity and transient in nature. Other common adverse events (≥5% and at least twice that of placebo) included abnormal ejaculation and anorgasmia.
Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of LUVOX CR® (fluvoxamine maleate) Extended-Release Capsules or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. LUVOX CR Capsules are not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.)
Please see full prescribing information, including boxed warning, for LUVOX CR.
LUVOX CR is a registered trademark of Solvay Pharmaceuticals, Inc.
© 2008 Jazz Pharmaceuticals, Inc.
